[Anti-angiogenesis and molecular targeted therapies].
Tumor angiogenesis contributes to the development of tumor progression. Several vascular endothelial growth factor(VEGF)-targeted agents, administered either as single agents or in combination with chemotherapy, have been shown to benefit patients with advanced-stage malignancies. In particular, bevacizumab is a humanized monoclonal antibody that specifically targets VEGF, inhibiting angiogenesis, thereby impeding tumor growth and survival. It is also possible that combined VEGF and the epidermal growth factor (EGFR) pathway blockade could further enhance antitumor efficacy and help prevent resistance to therapy. Preclinical and clinical studies have shown new various molecular targets and the functional characteristics of tumor angiogenesis, which may provide strategies for improving the therapeutic benefit.
Akihiko
A
Miyanaga
Akihiko
A
Gemma
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D007211:Indoles; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D009841:Oligonucleotides; D010671:Phenylurea Compounds; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011758:Pyrroles; D011799:Quinazolines; D000077157:Sorafenib; D000077210:Sunitinib; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000502:physiology
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D009841:Oligonucleotides; D010671:Phenylurea Compounds; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D011799:Quinazolines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; C519562:imetelstat; D000077210:Sunitinib; C452423:vandetanib